16.01.2009 21:40

Advanced Medical Optics Receives FDA Approval for TECNIS® Multifocal Intraocular Lens


Advanced Medical Optics, Inc. (AMO) (NYSE:EYE), the global leader in advanced refractive technologies for eye care professionals and patients, today announced U.S. Food and Drug Administration (FDA) approval of the TECNIS® Multifocal intraocular lens (IOL) for cataract patients.

The TECNIS® Multifocal IOL’s unique design gives patients superior near vision and reading speed compared to other presbyopia-correcting IOLs, as well as exceptionally high spectacle independence, with nearly 9 out of 10 patients reporting that they never wear glasses after surgery.

Other features/benefits include:

  • high-quality vision for near, far and intermediate distances, day or night;
  • first and only pupil-independent, non-apodized fully diffractive aspheric lens designed to correct the two highest order aberrations – spherical and chromatic – to give patients back their youthful vision;
  • 95 percent patient satisfaction – the highest of any presbyopia-correcting IOL.

"The TECNIS® Multifocal IOL delivers a predictable and consistent full range of vision,” said Ralph Chu, M.D., founder and director of the Chu Vision Institute in Bloomington, Minn. "The U.S. clinical study shows that more than 94 percent of patients function comfortably without glasses for all distances, including intermediate. More importantly, my own patients are highly satisfied with the results.”

"The full diffractive surface of the TECNIS® Multifocal IOL provides high-quality vision largely independent of pupil size and reduces chromatic aberration for better image quality,” said Manfred Tetz, M.D., professor of ophthalmology and director of Eye-Center-Spreebogen, Berlin, Germany. "I have been implanting the TECNIS® Multifocal IOL since 2003 because of the high-quality visual results that I can provide for my patients, who report being extremely satisfied with their vision.”

"The introduction of the TECNIS® Multifocal IOL in the U.S. rounds out AMO’s portfolio of market-leading, refractive technologies,” said AMO Chairman and CEO Jim Mazzo. "Following years of success in Europe, U.S. surgeons will soon be able to pass the benefits of this technology on to their patients.”

TECNIS® Multifocal IOLs are indicated for primary implantation for the visual correction of aphakia in adult patients with and without presbyopia in whom a cataractous lens has been removed by phacoemulsification and who desire near, intermediate, and distance vision with increased spectacle independence. The IOLs are intended to be placed in the capsular bag.

AMO plans to ship TECNIS® Multifocal IOLs to U.S. surgeons in early 2009.

About Advanced Medical Optics (AMO)

AMO is focused on providing the full range of advanced refractive technologies and support to help eye care professionals deliver optimal vision and lifestyle experiences to patients of all ages. Products in the cataract line include monofocal intraocular lenses (IOLs), phacoemulsification systems, viscoelastics, and related products used in ocular surgery. AMO owns or has the rights to such product brands as Tecnis®, Clariflex® and Sensar® IOLs; Sovereign®, Sovereign® Compact and WhiteStar Signature phacoemulsification systems with WhiteStar® technology; Healon® viscoelastics and the Baerveldt® glaucoma shunt. Products in the refractive line include wavefront diagnostic devices, femtosecond lasers and associated patient interface devices; excimer laser vision correction systems and treatment cards, and refractive implants. AMO brands in the refractive business include iDesign, iFS, Star S4 IR®, WaveScan Wavefront®, Advanced CustomVue, IntraLase®, IntraLasik® and ReZoom®, Tecnis® Multifocal and Verisyse® IOLs. Products in the eye care line include disinfecting solutions, enzymatic cleaners, lens rewetting drops and artificial tears. Among the eye care product brands the company possesses are COMPLETE®, COMPLETE® Blink-N-Clean®, Consept®F, Consept® 1 Step, Oxysept® 1 Step, UltraCare®, Ultrazyme®, Total Care and blink® branded products. AMO is based in Santa Ana, California, and employs approximately 3,700 worldwide. The company has operations in 27 countries and markets products in approximately 60 countries. For more information, visit the company's Website at

Forward-Looking Statements

This press release contains forward-looking statements about AMO, including statements by Dr. Chu, Dr. Tetz and Mr. Mazzo, and statements relating to expected product performance and anticipated outcomes, as well as expected shipment dates. All forward-looking statements in this press release represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements. Additional information concerning these and other risk factors may be found in previous press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2007 Form 10-K filed in March 2008 and its Form 10-Q filed in November 2008. Copies of press releases and additional information about AMO are available at

Nachrichten zu Abbott Laboratories

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Abbott Laboratories

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
19.10.2017Abbott Laboratories OutperformRBC Capital Markets
16.10.2018Abbott Laboratories OverweightBarclays Capital
25.01.2018Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
15.12.2017Abbott Laboratories OutperformBMO Capital Markets
19.10.2017Abbott Laboratories BuyStifel, Nicolaus & Co., Inc.
19.10.2017Abbott Laboratories OutperformRBC Capital Markets
23.07.2015Abbott Laboratories Equal WeightBarclays Capital
27.03.2015Abbott Laboratories Equal WeightBarclays Capital
30.01.2015Abbott Laboratories Equal WeightBarclays Capital
07.01.2013Abbott Laboratories haltenDeutsche Bank Securities
29.11.2012Abbott Laboratories neutralSarasin Research
25.10.2011Abbott Laboratories sellCitigroup Corp.
05.10.2011Abbott Laboratories sellCitigroup Corp.
22.11.2006Advanced Medical Optics sellCitigroup
11.09.2006Abbott Laboratories reduceUBS
06.10.2005Update Abbott Laboratories: ReduceUBS

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Abbott Laboratories nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX schließt mit kleinem Minus -- Dow letztendlich fester -- Lufthansa mit Gewinnwarnung für 2019 -- Deutsche Bank plant wohl milliardenschwere Bad Bank -- BASF, Bitcoin, 1&1, United Internet im Fokus

Facebook-Aktie klettert: Anleger schwelgen in Krypto-Euphorie. Siltronic kassiert erneut die Jahresziele. Infineon zapft Kapitalmarkt an für Übernahme von US-Firma Cypress. Chanel-Aktie als Börsenkandidat? Fusion von Sprint und T-Mobile dürfte wohl genehmigt werden. US-Sanktionen: Huawei erwartet kräftiges Umsatzminus.

Die 5 beliebtesten Top-Rankings

Das hat sich geändert
Diese Aktien hat George Soros im Depot
In welchen Ländern kostet der Big Mac wie viel?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
mehr Top Rankings


Glauben Sie die Anschuldigung der USA, dass der Iran für die Angriffe gegen Tanker im Golf von Oman verantwortlich ist?

Online Brokerage über Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von!


Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Wirecard AG747206
Lufthansa AG823212
Deutsche Bank AG514000
Daimler AG710000
Beyond MeatA2N7XQ
Infineon AG623100
Microsoft Corp.870747
Apple Inc.865985